Comparison of peptide-major histocompatibility complex tetramers and dextramers for the identification of antigen-specific T cells

Clinical and Experimental Immunology

Volumn 177, Issue 1, 2014, Pages 47-63

  Dolton, G ^a   Lissina, A ^a   Skowera, A ^b,f   Ladell, K ^a   Tungatt, K ^a   Jones, E ^a   Kronenberg Versteeg, D ^b   Akpovwa, H ^a   Pentier, J M ^a   Holland, C J ^a   Godkin, A J ^a   Cole, D K ^a   Neller, M A ^c   Miles, J J ^a,c,d   Price, D A ^a,e   Peakman, M ^b   Sewell, A K ^a  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Autoimmunity; Diabetes; T cell receptors; T cells; Tumour immunology

Indexed keywords

CD14 ANTIGEN; CD19 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; DASATINIB; DEXTRAMER; DEXTRAN; FLUOROCHROME; GAMMA INTERFERON; HLA A2 ANTIGEN; MELAN A; MELANOMA ANTIGEN; POLYMER; TETRAMER; UNCLASSIFIED DRUG;

ANTIGEN SPECIFICITY; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; DOWN REGULATION; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; LYMPHOCYTE SUBPOPULATION; MAJOR HISTOCOMPATIBILITY COMPLEX; PEPTIDE MAJOR HISTOCOMPATIBILITY COMPLEX; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

AUTOIMMUNITY; DIABETES; T CELL RECEPTORS; T CELLS; TUMOUR IMMUNOLOGY;

BIOTIN; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CELL SEPARATION; CLONE CELLS; DEXTRANS; FLOW CYTOMETRY; FLUORESCENT DYES; HEMAGGLUTININS, VIRAL; HLA-A2 ANTIGEN; HLA-DR1 ANTIGEN; HUMANS; INSULIN; MAJOR HISTOCOMPATIBILITY COMPLEX; PEPTIDE FRAGMENTS; PROTEIN BINDING; PROTEIN PRECURSORS; STREPTAVIDIN; T-CELL ANTIGEN RECEPTOR SPECIFICITY; TELOMERASE;

EID: 84904240682     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12339     Document Type: Article

References (40)

1. Wooldridge L, Lissina A, Cole DK, van den Berg HA, Price DA, Sewell AK. Tricks with tetramers: how to get the most from multimeric peptide-MHC. Immunology 2009; 126:147-164.
2. Klenerman P, Cerundolo V, Dunbar PR. Tracking T cells with tetramers: new tales from new tools. Nat Rev Immunol 2002; 2:263-272.
3. Newell EW, Sigal N, Bendall SC, Nolan GP, Davis MM. Cytometry by time-of-flight shows combinatorial cytokine expression and virus-specific cell niches within a continuum of CD8+ T cell phenotypes. Immunity 2012; 36:142-152.
4. Altman JD, Moss PA, Goulder PJ etal. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996; 274:94-96.
5. Batard P, Peterson DA, Devevre E etal. Dextramers: new generation of fluorescent MHC class I/peptide multimers for visualization of antigen-specific CD8+ T cells. J Immunol Methods 2006; 310:136-148.
6. Laugel B, van den Berg HA, Gostick E etal. Different T cell receptor affinity thresholds and CD8 coreceptor dependence govern cytotoxic T lymphocyte activation and tetramer binding properties. J Biol Chem 2007; 282:23799-23810.
7. Cole DK, Pumphrey NJ, Boulter JM etal. Human TCR-binding affinity is governed by MHC class restriction. J Immunol 2007; 178:5727-5734.
8. Vollers SS, Stern LJ. Class II major histocompatibility complex tetramer staining: progress, problems, and prospects. Immunology 2008; 123:305-313.
9. Choi EM, Chen JL, Wooldridge L etal. High avidity antigen-specific CTL identified by CD8-independent tetramer staining. J Immunol 2003; 171:5116-5123.
10. Choi EM, Palmowski M, Chen J, Cerundolo V. The use of chimeric A2K(b) tetramers to monitor HLA A2 immune responses in HLA A2 transgenic mice. J Immunol Methods 2002; 268:35-41.
11. Wooldridge L, Hutchinson SL, Choi EM etal. Anti-CD8 antibodies can inhibit or enhance peptide-MHC class I (pMHCI) multimer binding: this is paralleled by their effects on CTL activation and occurs in the absence of an interaction between pMHCI and CD8 on the cell surface. J Immunol 2003; 171:6650-6660.
12. Wooldridge L, Laugel B, Ekeruche J etal. CD8 controls T cell cross-reactivity. J Immunol 2010; 185:4625-4632.
13. Wooldridge L, Lissina A, Vernazza J etal. Enhanced immunogenicity of CTL antigens through mutation of the CD8 binding MHC class I invariant region. Eur J Immunol 2007; 37:1323-1333.
14. Wooldridge L, Scriba TJ, Milicic A etal. Anti-coreceptor antibodies profoundly affect staining with peptide-MHC class I and class II tetramers. Eur J Immunol 2006; 36:1847-1855.
15. Wooldridge L, van den Berg HA, Glick M etal. Interaction between the CD8 coreceptor and major histocompatibility complex class I stabilizes T cell receptor-antigen complexes at the cell surface. J Biol Chem 2005; 280:27491-27501.
16. Massilamany C, Upadhyaya B, Gangaplara A, Kuszynski C, Reddy J. Detection of autoreactive CD4 T cells using major histocompatibility complex class II dextramers. BMC Immunol 2011; 12:40.
17. Daniels MA, Jameson SC. Critical role for CD8 in T cell receptor binding and activation by peptide/major histocompatibility complex multimers. J Exp Med 2000; 191:335-346.
18. Clement M, Ladell K, Ekeruche-Makinde J etal. Anti-CD8 antibodies can trigger CD8+ T cell effector function in the absence of TCR engagement and improve peptide-MHCI tetramer staining. J Immunol 2011; 187:654-663.
19. Lissina A, Ladell K, Skowera A etal. Protein kinase inhibitors substantially improve the physical detection of T-cells with peptide-MHC tetramers. J Immunol Methods 2009; 340:11-24.
20. Purbhoo MA, Li Y, Sutton DH etal. The HLA A*0201-restricted hTERT(540-548) peptide is not detected on tumor cells by a CTL clone or a high-affinity T-cell receptor. Mol Cancer Ther 2007; 6:2081-2091.
21. Laugel B, Price DA, Milicic A, Sewell AK. CD8 exerts differential effects on the deployment of cytotoxic T lymphocyte effector functions. Eur J Immunol 2007; 37:905-913.
22. Bulek AM, Cole DK, Skowera A etal. Structural basis for the killing of human beta cells by CD8(+) T cells in type 1 diabetes. Nat Immunol 2012; 13:283-289.
23. Skowera A, Ellis RJ, Varela-Calvino R etal. CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope. J Clin Invest 2008; 118:3390-3402.
24. Kronenberg D, Knight RR, Estorninho M etal. Circulating preproinsulin signal peptide-specific CD8 T cells restricted by the susceptibility molecule HLA-A24 are expanded at onset of type 1 diabetes and kill beta-cells. Diabetes 2012; 61:1752-1759.
25. Stern LJ, Brown JH, Jardetzky TS etal. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 1994; 368:215-221.
26. Nunes CT, Miners KL, Dolton G etal. A novel tumor antigen derived from enhanced degradation of bax protein in human cancers. Cancer Res 2011; 71:5435-5444.
27. Cole DK, Laugel B, Clement M, Price DA, Wooldridge L, Sewell AK. The molecular determinants of CD8 co-receptor function. Immunology 2012; 137:139-148.
28. Laugel B, Cole DK, Clement M, Wooldridge L, Price DA, Sewell AK. The multiple roles of the CD8 coreceptor in T cell biology: opportunities for the selective modulation of self-reactive cytotoxic T cells. J Leukoc Biol 2012; 90:1089-1099.
29. Killeen N, Littman DR. The regulation and function of the CD4 coreceptor during T lymphocyte development. Curr Top Microbiol Immunol 1996; 205:89-106.
30. Gao GF, Willcox BE, Wyer JR etal. Classical and nonclassical class I major histocompatibility complex molecules exhibit subtle conformational differences that affect binding to CD8αα. J Biol Chem 2000; 275:15232-15238.
31. Purbhoo MA, Boulter JM, Price DA etal. The human CD8 coreceptor effects cytotoxic T cell activation and antigen sensitivity primarily by mediating complete phosphorylation of the T cell receptor zeta chain. J Biol Chem 2001; 276:32786-32792.
32. Bakker AH, Schumacher TN. MHC multimer technology: current status and future prospects. Curr Opin Immunol 2005; 17:428-433.
33. Pittet MJ, Rubio-Godoy V, Bioley G etal. Alpha 3 domain mutants of peptide/MHC class I multimers allow the selective isolation of high avidity tumor-reactive CD8 T cells. J Immunol 2003; 171:1844-1849.
34. Boniface JJ, Rabinowitz JD, Wulfing C etal. Initiation of signal transduction through the T cell receptor requires the multivalent engagement of peptide/MHC ligands [corrected]. Immunity 1998; 9:459-466.
35. Crawford F, Kozono H, White J, Marrack P, Kappler J. Detection of antigen-specific T cells with multivalent soluble class II MHC covalent peptide complexes. Immunity 1998; 8:675-682.
36. Cole DK, Edwards ES, Wynn KK etal. Modification of MHC anchor residues generates heteroclitic peptides that alter TCR binding and T cell recognition. J Immunol 2010; 185:2600-2610.
37. Aleksic M, Liddy N, Molloy PE etal. Different affinity windows for virus and cancer-specific T-cell receptors: implications for therapeutic strategies. Eur J Immunol 2012; 42:3174-3179.
38. Pittet MJ, Valmori D, Dunbar PR etal. High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp Med 1999; 190:705-715.
39. Cole DK, Yuan F, Rizkallah PJ etal. Germ line-governed recognition of a cancer epitope by an immunodominant human T-cell receptor. J Biol Chem 2009; 284:27281-27289.
40. Whelan JA, Dunbar PR, Price DA etal. Specificity of CTL interactions with peptide-MHC class I tetrameric complexes is temperature dependent. J Immunol 1999; 163:4342-4348.